The global spread of COVID-19 has led to changes in routine clinical care in order to prevent nosocomial transmission of SARS-CoV2. One area this is impacted is kidney transplantation, where there is a particular need to avoid transmission of the virus from donors to immunosuppressed recipients. This session aims to describe the impact of COVID-19 on the supply of living and deceased donor kidneys.  

This presentation makes the case that focusing on childhood kidney disorders and the risk for such disorders will improve the identification and care of adults with kidney disease. By focusing on kidney disease in childhood, cost-effective solutions may be reached because treating the disease early and preemptively may avert later more advanced CKD. Expectations depend on the identification of those at risk, and the availability of care and management. Treating children who have AKI and CKD who may require long-term medication or who require RRT can be effective in mitigating the burden of kidney disease in adulthood. This presentation will discuss who these children are and how they might be followed.  

The session will explain the guideline development process and the benefits of multidisciplinary collaboration between the National Kidney Foundation and the Academy of Nutrition and Dietetics to produce global evidence-based nutrition guidelines for patients with chronic kidney disease. It will also help the audience recognize the differences between the KDOQI Nutrition 2000 and KDOQI Nutrition 2020 recommendations.  

This lecture will review the effects of  COVID-19 infection on kidney function and describe the risk of SARS Co-V-2 infection in dialysis patients.

In this lecture there will be a review of the neuropathology of Alzheimer's disease (AD), along with a discussion of current treatments in development. The effects of hemodialysis on AD biomarkers and pathology will be discussed. In addition, there will be a discussion of the recent results of the AMBAR phase 2b/3 clinical trial of plasma exchange with albumin replacement as a treatment for AD.  

Upon the completion of this session, participants should be better able to identify patients affected by sleep apnea in CKD, describe the risk for death and cardiovascular events in CKD patients, and make treatment decisions for their patients.

The future of nephrology depends on improved understanding epidmiology, improved clinical research participation and translation of understandings to improve care. Globally, the nephrology community has an opportunity to improve patient outcomes through advocacy, research and education. This talk focuses on some of the current disparities in access to care( including dialysis) and research as well as offering a paradigm and framework in which to conceptualize these issues.  

In this session Dr. Thadhani reviews how testing for SARS-CoV-2 evolved in the US, with a specific emphasis on how different test characteristics were needed depending on how they are being used. Sensitivity and Ro are highlighted in modeling how frequently testing should be done to contain the spread of SARS-CoV-2. Finally, there is a review of the spread of specific variants and how testing is critical to map the spread of variants.  

Treating disease early and preemptively may avert later more advanced CKD. Expectations depend on the identification of those at risk, and the availability of care and management. Treating children who have AKI and CKD who may require long-term medication or who require RRT can be effective in mitigating the burden of kidney disease in adulthood. This presentation will discuss who these children are and how they might be followed.